Evidence map›Paper›PMID 36999215›Full record

ArticleJournal of diabetes science and technology2024

Glycemic Risk Index Profiles and Predictors Among Diverse Adults With Type 1 Diabetes.

Claire J Hoogendoorn, Raymond Hernandez, Stefan Schneider, Mark Harmel, Loree T Pham, Gladys Crespo-Ramos, Shivani Agarwal, Jill Crandall, Anne L Peters, Donna Spruijt-Metz and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Claire J HoogendoornFerkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.ORCID 0000-0003-4526-1952
Raymond HernandezChan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, USA.
Stefan SchneiderCenter for Economic and Social Research, University of Southern California, Los Angeles, CA, USA.
Mark HarmelKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Loree T PhamChan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, USA.
Gladys Crespo-RamosDivision of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Shivani AgarwalDivision of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Jill CrandallDivision of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Anne L PetersKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Donna Spruijt-MetzCenter for Economic and Social Research, University of Southern California, Los Angeles, CA, USA.
Jeffrey S GonzalezFerkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.
Elizabeth A PyatakChan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, USA.

Funding

Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Shuibing Chen · 2015 to 2026
$27.7M
New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
Function and Emotion in Everyday Life with Type 1 Diabetes: FEEL-T1DR01DK121298 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GONZALEZ, JEFFREY S, PYATAK, ELIZABETH F · 2019 to 2022
$3.2M
Identifying and Reducing Disparities in Outcomes Among Economically Vulnerable and Minority Young Adults with Type 1 DiabetesK23DK115896 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI AGARWAL, SHIVANI · 2018 to 2022
$988k
NIDDK NIH HHS K23 DK115896NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P30 DK111022NIDDK NIH HHS R01 DK121298
6 · The paper itself

Abstract

backgroundThe Glycemia Risk Index (GRI) was introduced as a single value derived from the ambulatory glucose profile that identifies patients who need attention. This study describes participants in each of the five GRI zones and examines the percentage of variation in GRI scores that is explained by sociodemographic and clinical variables among diverse adults with type 1 diabetes.

methodsA total of 159 participants provided blinded continuous glucose monitoring (CGM) data over 14 days (mean age [SD] = 41.4 [14.5] years; female = 54.1%, Hispanic = 41.5%). Glycemia Risk Index zones were compared on CGM, sociodemographic, and clinical variables. Shapley value analysis examined the percentage of variation in GRI scores explained by different variables. Receiver operating characteristic curves examined GRI cutoffs for those more likely to have experienced ketoacidosis or severe hypoglycemia.

resultsMean glucose and variability, time in range, and percentage of time in high, and very high, glucose ranges differed across the five GRI zones (

conclusionsResults support the use of the GRI, with GRI zones identifying those in need of clinical attention. Findings highlight the need to address health inequities. Treatment differences associated with the GRI also suggest behavioral and clinical interventions including starting individuals on CGM or automated insulin delivery systems.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1AdultFemaleHumansHypoglycemiaMaleMiddle AgedRisk AssessmentRisk FactorsBlood Glucoseautomated insulin delivery systemscontinuous glucose monitoringdiabetes self-managementglycemic risk indexhealth inequitiestype 1 diabetes

Identifiers

PMID36999215
PMCPMC11418469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.